Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BPTH NASDAQ:JAGX NASDAQ:QLGN NASDAQ:VRAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPTHBio-Path$0.04-17.4%$0.04$0.01▼$0.17$1.91M-0.5125,263 shs847 shsJAGXJaguar Animal Health$2.66-5.3%$3.62$2.12▼$97.65$1.60M-0.1197,820 shs24,833 shsQLGNQualigen Therapeutics$1.09-0.9%$1.31$1.61▼$8.81$1.85M0.241.52 million shs66,053 shsVRAXVirax Biolabs Group$3.04-2.3%$4.43$2.50▼$28.50$2.42M1.35637,030 shs114,338 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPTHBio-Path-2.13%+42.86%+31.43%-11.71%-73.07%JAGXJaguar Animal Health0.00%-5.07%+0.36%-80.39%-96.87%QLGNQualigen Therapeutics0.00%+1.85%-5.17%-19.71%-66.25%VRAXVirax Biolabs Group-0.64%-4.60%-41.46%-11.14%-85.62%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPTHBio-Path$0.04-17.4%$0.04$0.01▼$0.17$1.91M-0.5125,263 shs847 shsJAGXJaguar Animal Health$2.66-5.3%$3.62$2.12▼$97.65$1.60M-0.1197,820 shs24,833 shsQLGNQualigen Therapeutics$1.09-0.9%$1.31$1.61▼$8.81$1.85M0.241.52 million shs66,053 shsVRAXVirax Biolabs Group$3.04-2.3%$4.43$2.50▼$28.50$2.42M1.35637,030 shs114,338 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPTHBio-Path-2.13%+42.86%+31.43%-11.71%-73.07%JAGXJaguar Animal Health0.00%-5.07%+0.36%-80.39%-96.87%QLGNQualigen Therapeutics0.00%+1.85%-5.17%-19.71%-66.25%VRAXVirax Biolabs Group-0.64%-4.60%-41.46%-11.14%-85.62%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPTHBio-Path 0.00N/AN/AN/AJAGXJaguar Animal Health 1.00SellN/AN/AQLGNQualigen Therapeutics 1.00SellN/AN/AVRAXVirax Biolabs Group 2.00Hold$25.00722.37% UpsideCurrent Analyst Ratings BreakdownLatest VRAX, QLGN, JAGX, and BPTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026JAGXJaguar Animal Health Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/8/2026VRAXVirax Biolabs Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 7/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPTHBio-PathN/AN/AN/AN/A$0.71 per shareN/AJAGXJaguar Animal Health$11.51M0.14N/AN/A($106.11) per share-0.03QLGNQualigen TherapeuticsN/AN/AN/AN/A($4.12) per shareN/AVRAXVirax Biolabs Group$2.99K811.41N/AN/A$31.45 per share0.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPTHBio-Path-$16.08M-$1.09N/AN/AN/AN/A-2,842.40%-337.48%8/18/2026 (Estimated)JAGXJaguar Animal Health-$53.43M-$591.92N/AN/AN/A-169.04%N/A-115.55%8/13/2026 (Estimated)QLGNQualigen Therapeutics-$6.26M-$7.50N/AN/AN/AN/AN/A-202.16%N/AVRAXVirax Biolabs Group-$6.06MN/AN/AN/AN/AN/AN/AN/AN/ALatest VRAX, QLGN, JAGX, and BPTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/3/2026Q4 2026VRAXVirax Biolabs Group-$1.75-$0.1950+$1.5550-$0.1950$0.00 million$0.01 million5/20/2026Q1 2026JAGXJaguar Animal Health-$149.10-$13.60+$135.50-$13.60$4.21 million$20.27 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBPTHBio-PathN/AN/AN/AN/AN/AJAGXJaguar Animal HealthN/AN/AN/AN/AN/AQLGNQualigen TherapeuticsN/AN/AN/AN/AN/AVRAXVirax Biolabs GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPTHBio-PathN/A0.860.86JAGXJaguar Animal HealthN/A0.500.30QLGNQualigen TherapeuticsN/A0.710.71VRAXVirax Biolabs GroupN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPTHBio-Path5.74%JAGXJaguar Animal Health12.04%QLGNQualigen Therapeutics3.18%VRAXVirax Biolabs Group8.61%Insider OwnershipCompanyInsider OwnershipBPTHBio-Path0.72%JAGXJaguar Animal Health2.00%QLGNQualigen Therapeutics1.80%VRAXVirax Biolabs Group45.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBPTHBio-Path1050.30 million5.73 millionNo DataJAGXJaguar Animal Health50600,000591,000No DataQLGNQualigen Therapeutics501.70 million1.66 millionNot OptionableVRAXVirax Biolabs Group5797,000438,000Not OptionableVRAX, QLGN, JAGX, and BPTH HeadlinesRecent News About These CompaniesVirax Biolabs Group (NASDAQ:VRAX) Downgraded by Wall Street Zen to "Sell"July 5 at 1:12 AM | americanbankingnews.comVirax Biolabs Group (NASDAQ:VRAX) Upgraded by Wall Street Zen to Hold RatingJune 27, 2026 | americanbankingnews.comVirax Biolabs Group Shares Set to Reverse Split on Monday, June 29th (NASDAQ:VRAX)June 25, 2026 | americanbankingnews.comVirax Biolabs Group announces 1-for-25 share consolidationJune 25, 2026 | msn.comVirax Biolabs Approves 1-for-25 Share Consolidation to Maintain Nasdaq ListingJune 24, 2026 | tipranks.comVirax Biolabs Group Limited Announces 1-for-25 Share ConsolidationJune 24, 2026 | prnewswire.comVirax BioLabs Group Limited: Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune in Long COVID and Related Post-Acute Infection SyndromesMay 26, 2026 | finanznachrichten.deVirax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection SyndromesMay 26, 2026 | prnewswire.comVirax Biolabs Calls June 5 EGM to Approve Reverse Share Split and Charter AmendmentsMay 22, 2026 | tipranks.comWhy Is Virax Biolabs (VRAX) Stock Trending Overnight?May 19, 2026 | benzinga.comVirax Biolabs (VRAX) surges 177% as low-float momentum meets extreme short interestMay 18, 2026 | quiverquant.comQAvalon Advanced Materials and Virax Biolabs Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVMay 15, 2026 | corsicanadailysun.comCVirax Biolabs Group Ltd - Ordinary Shares - Class AMay 13, 2026 | money.usnews.comVirax Biolabs Group Limited Or Stock Short Interest Rises to 71.68%April 25, 2026 | quiverquant.comQVirax Biolabs Group Ltd. Class AApril 24, 2026 | edition.cnn.comVirax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to ShareholdersApril 14, 2026 | prnewswire.comVirax Biolabs Announces Full Exercise of Pre-Funded Warrants From $5 Million Private PlacementApril 10, 2026 | tipranks.comWhat's Behind The Jump In Virax Biolabs Stock?March 31, 2026 | benzinga.comVirax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical ValidationMarch 31, 2026 | prnewswire.comVirax Biolabs Group (VRAX) price target decreased by 95.00% to 1.02February 5, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVRAX, QLGN, JAGX, and BPTH Company DescriptionsBio-Path NASDAQ:BPTH$0.04 -0.01 (-17.39%) As of 12:06 PM EasternBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.Jaguar Animal Health NASDAQ:JAGX$2.66 -0.15 (-5.34%) Closing price 04:00 PM EasternExtended Trading$2.57 -0.09 (-3.35%) As of 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.Qualigen Therapeutics NASDAQ:QLGN$1.09 -0.01 (-0.91%) As of 07/6/2026Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.Virax Biolabs Group NASDAQ:VRAX$3.04 -0.07 (-2.25%) Closing price 04:00 PM EasternExtended Trading$3.11 +0.07 (+2.27%) As of 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity Palantir's CEO Just Called Out OpenAI and Anthropic Silicon Starvation: Amazon Feasts on Legacy GPUs GE Vernova’s Power Surge Turns the Grid Into an AI Trade 3 Quiet AI Revenue Accelerators With Sales Growth Outpacing Peers Abivax: Wall Street Catches Up to the Data AI Insider Activity: Are Sales Across 3 Key Stocks Noteworthy or Just Noise? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
